
ASX Announcement and Media Release

14 October 2004

SciGen Limited

National Award recognises SciGen's Continuing Growth and Success

International biopharmaceutical Company SciGen Limited ("SciGen") last night received an award in BRW magazine's Fast 100 – recognition given to the top 100 fastest growing companies in Australia. This is the second consecutive year that SciGen has received this award. SciGen achieved 35th place in the top 100 (placed 44th in 2003).

Mark Compton, SciGen's Managing Director said "this is further independent recognition of SciGen's growing success as it commercialises its product portfolio and rapidly increases its revenue stream. We are very pleased to receive this award in 2 consecutive years, which is further recognition of our sustainable growth".

"I want to personally thank our great team at SciGen for their wonderful contribution to the company winning this Award. My thanks also go to our customers, partners & shareholders for their ongoing support" Mr Compton said.

Highlights of SciGen's performance for FY2004 include:

Financial Highlights:

- Revenue increase by 79% from prior year to S\$6.48M
- Cash receipts from customers up 173% from prior year to S\$5.4M
- Net cashflow from operating activities improved by S\$2.37M or 34% over the prior year
- Cash at bank at the end of the period S\$9.56M

Operational Highlights:

- Launch of recombinant human insulin (SciLinTM) in Vietnam
- Sales of recombinant human insulin (SciLinTM) commenced in Pakistan
- Considerable growth in SciTropinTM (recombinant human growth hormone) sales in Australia and Korea
- Registration (post balance date) of SciLinTM in India
- Registration of SciTropinTM in India with sales expected to commence during FY2005
- Sci-B-VacTM (3rd generation hepatitis B vaccine) registered in Singapore
- Negotiation of commercialization agreement for SciLinTM in China
- Favourable renegotiation of licence agreement for Sci-B-VacTM providing extended licence term; extension of supply rights (as distinct from marketing rights) from Asia Pacific region only to Worldwide rights; acquisition of rights for any hepatitis B therapeutic vaccine developed and Asia Pacific rights for combination vaccine.
- Announcement of discussions regarding potential strategic investment in the company.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries: Mark Compton, Managing Director & CEO
Telephone: +61 2 9234 1700; Web: www.scigen.com.au